39 results about "Retinal Photoreceptor Cells" patented technology

Disclosed is a system for maintaining normal health of photoreceptor cells and promoting regeneration of photoreceptor cells, and methods thereof. The system comprises: an implant capable of being implanted in a region in proximity to retina of an eye; and an electrical stimulation unit disposed in a region around the eye. The electrical stimulation unit induces an electrical current in the implant for electrical stimulation of the retina of the eye, thereby maintaining normal health of photoreceptor cells and promoting regeneration of photoreceptor cells in the retina.

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system, such as the retina. The present invention provide agents which are able to diffuse readily and therefore can promote repair for neurodegenerative disease of the eye, such as macular degeneration. The present invention further provides methods of treating macular degeneration, methods of inhibiting or reducing the rate of subretinal neovascularization and proliferation of neovascular tissue and methods of protecting retinal photoreceptor cell death.

The invention provides a light green goggle lens for prevention of an electronic luminescent screen hurts. The lens is composed of a substrate and an evaporation coating film layer, wherein the substrate contains a short-wave visible light absorbing agent and is made of organic high-molecular polymers containing an ultraviolet absorbing agent. The lens can almost completely absorb ultraviolet rays and high-energy purple and blue visible light which are emitted by the electronic luminescent screen, hurts of ultraviolet rays and short-wavelength photons to retinas are avoided, simultaneously, almost no color difference exists, and the lens has the low color temperature, so that eyes are in the environment close to the nature, the normal growth and development of retina photosensory cells are not influenced and hurt, and the lens is applicable to growing youngsters.

The invention relates to a co-culture method of photosensory precursor cells and retinal tissue in vitro and aims to build a co-culture system for the photosensory precursor cells and denaturation retinal tissue of retina photoreceptor cells. The method comprises the following steps: a photosensory precursor cell layer of an embryonic eye source is prepared; a nerve cell layer of a denatured retina is prepared; the nerve cell layer of the denatured retina is placed on the photosensory precursor cell layer; an epithelial layer of retinochrome is prepared in the lower chamber of a plug-in type tissue culture dish; the co-culture system of the retinal tissue and cells is built in vitro, and the retinal tissue and cells are cultured in an incubator with 5% CO2 at the temperature of 37 DEG C. By adopting the method provided by the invention, the biological characteristics and cellular structure of host cells and transplanted cells, the synaptic contact of the transplanted cells and the host cells, and the chromatin conformation reconstruction of the transplanted cells and the host cells can be observed and detected directly in vitro, and the traces of survival, proliferation, differentiation and functional reconstruction of photosensory precursor cells of a transplanted embryonic eye source can be tracked.

The invention relates to a contour detection method based on visual mechanism dark edge enhancement. The method comprises the following steps: firstly, simulating retina photoreceptor cell response characteristics, and proposing a dark field adjustment model based on local brightness characteristics; then, in combination with the scale orientation characteristic of the classical receptive field ofthe ganglion cells, obtaining a primary contour response, and extracting global contour information by utilizing a principal component analysis method; then, when a retinal ganglion signal is transmitted to an outer knee body, simulating a side inhibition effect of a non-classical receptive field, further introducing a nerve cell sparse response characteristic, and cooperatively inhibiting a background strong texture of a primary contour; simulating the enhancement effect of micro-motion information on contour perception understanding so that background weak textures are reduced, and then using adaptive dynamic synapses for outputting and transmitting external knee body impulse responses to a primary visual cortex; and finally, correcting the primary contour response through global contour information, and outputting and quickly fusing the corrected primary contour response with the primary visual cortex response to generate a more accurate and effective contour detection result.

The invention discloses an apocynin water-soluble prodrug having a structure in a general formula I as shown below in the specification, a preparation method and application thereof in preparation of drugs for preventing and / or treating retinal degenerative diseases. The apocynin prodrug disclosed by the invention has favorable water solubility, higher oral bioavailability and remarkable activity of in vivo preventing light injury to retinal photoreceptor cells. The general formula I is shown in the specification.

People with (AMD) Adult Macular Degeneration have great difficulty seeing, because their damaged retina sees double vision and distortion. The vision loss is a deterioration of light sensing cells of the retina. Direct or reflecting sunlight and headlights cause extreme glaring and distortion. There are magnifying binocular-fitted eyeglasses for precise detail, and an eye patch, which entirely blocks out all vision, which puts strain and pressure on the dominant eye. Not much is offered to block bright glare, distorted images and double vision associated with AMD.This invention enables adults and children with AMD to self-apply a stick-on eyeglass multi-colored filter UV protectant disc, placed only in front of the affected eye's pupil, on the front of the eyeglass lens. An eye patch blocks all vision completely. However, this invention is an improvement, by which the user chooses optional translucent or solid multi colored, self-applied color filter discs, having different elective properties, which blocks only the affected retina from bright sun, reflections, headlight glare, double vision and distortion, without affecting the users peripheral (side view) vision.

The invention relates to a flavonoid organic effective component-containing medicinal preparation, in particular to the application of naringenin in preparing medicines for resisting apoptosis of a retinal photoreceptor cell. According to the application, the compound naringenin embodying the uses has a protective action on the photochemical damage of the retinal photoreceptor cell, can be used for resisting the apoptosis of the retinal photoreceptor cell and can be used for preparing various medicines for resisting the apoptosis of the retinal photoreceptor cell so as to be in favor of increasing the life quality of human.

The invention relates to the technical field of medicaments, in particular to application of tamoxifen in preparation of a medicament for protecting retina photoreceptor cells. According to the application, mouse models with subretinal hemorrhage caused by an autologous blood injection mode are adopted; research shows that the survival rate of the retina photoreceptor cells which are in contact with blood can be improved, the apoptosis rate of the retina photoreceptor cells can be reduced, and the thickness of a retina outer nuclear layer can be maintained by giving the tamoxifen. A protectingeffect on the retina photoreceptor cells can be applied in a protective manner, namely, the tamoxifen is used when new vessels do not burst. Based on experimental results, the protecting effect can also be achieved on surviving retina photoreceptor cells in a retina even after bleeding. The tamoxifen can change an electroretinogram waveform of a normal mouse, which is one of the mechanisms for protecting the retina photoreceptor cells.

The invention relates to a retinal photoreceptor cell specificity surface protein screening method. The photoreceptor cell specificity surface protein can be screened out, specificity of the surface protein is specifically expressed on the surfaces of retinal photoreceptor cell membranes sourced from human embryonic stem cells and human multipotential stem cells, and a simple method is provided for purifying retinal photoreceptor cells source from the human multipotential stem cells. The purified photoreceptor cells obtained by screening the surface protein can avoid the potential danger caused by transgenosis or utilizing varieties of small molecule compound as inducers. As the key scientific problem is solved, a process for converting the stem cells to clinic is quickened, medical research need is met, and foundation of cell replacement therapy on human retinal related diseases (such as glaucoma, macula lutea eye disease and the like is established.

The invention discloses a buddleja officinalis extract, a preparation method thereof, and an application of the buddleja officinalis extract to preparation of a medicine for treating or preventing retinal degenerative changes. The buddleja officinalis extract is obtained by extracting buddleja officinalis with an aqueous solution, and the total weight of five compounds including apigenin-7,4'-di-O-beta-D-glucosiduronic acid, echinacoside, verbascoside, isoverbascoside and apigenin-7-O-rutinoside accounts for 10% or above of the total weight of the extract. Experiments prove that the extract has good inhibitory activity on VEGFR-1 and VEGFR-2, can significantly inhibit occurrence of retinal photoreceptor cell degenerative changes, and can be used for treating or preventing retinal degenerative changes.

The invention belongs to the technical field of semiconductor nano photosensitive materials, and relates to novel application of a semiconductor nanomaterial with a photosensitive effect, in particular to the application of a semiconductor nano photosensitive material in preparing a visual repair material. The semiconductor nano photosensitive material is similar to a retinal photoreceptor cell and is an ordered one-dimensional gold-modified titanium oxide nanowire array; the semiconductor nano photosensitive material has the advantages of high specific surface area, large material retinal interaction area, large charge mobility and good biocompatibility and stability, and is applied to both isolated retina and a living mouse by replacing a photoreceptor, so that the retina produces a photoreaction; the semiconductor nano photosensitive material can be used for preparing the visual repair material for repairing dysopia. Experiments confirm that the visual repair material can repair retinal ganglion cells to produce the photoreaction, thereby repairing visual cortical nerve cells to produce the photoreaction.

The invention belongs to the technical field of bioengineering and biomedicine, and relates to rAAV2 / Retro serving as a delivery system for retina photoreceptor cells and application of the rAAV2 / Retro in preparation of drugs for treating retinal diseases. The method comprises the following steps: constructing an expression system carrying an exogenous target gene or shRNA (short hairpin Ribonucleic Acid) by taking rAAV2 / Retro as a carrier; taking the rAAV2 / Retro as a delivery system to effectively infect retina photoreceptor cells and specifically express the target gene or knock out the endogenous gene. According to the invention, a unique reverse backtracking infection mode of rAAV2 / Retro is utilized to specifically act on photoreceptor cells, so that non-specificity of a traditional adeno-associated virus delivery system is avoided; the medicine for treating the retinal diseases adopts safe and comprehensive intravitreal injection, the infection range is larger than that of traditional adeno-associated viruses, and a better treatment effect is achieved. Therefore, the gene medicine for treating the retinal diseases, which is prepared by utilizing the rAAV2 / Retro virus carrier disclosed by the invention, has the advantages of strong specificity, high safety and good treatment effect.

The present invention discloses a novel intraocular lens system. The system includes a rear set of lens and a front set of lens, the rear set of lens includes at least one first lens and the rear setof lens abuts the front side of the posterior capsule inside the eyeball, the front set of lens also includes at least one second lens and the front set of lens is disposed on the side of the iris inside the eyeball, the front set of lens and the rear set of lens form a rotational symmetric imaging system around the optical axis of the eyeball, the first lens is specifically a positive-dioptric single-positive lens with a front light-transmission surface and a rear light-transmission surface, at least one of the front light-transmission surface and the rear light-transmission surface is an aspheric surface, and the second lens is specifically a negative-dioptric single-positive lens with a front light-transmission surface and a rear light-transmission surface. Through the positions of therear set of lens and the front set of lens, the dynamic adjustment of the clear region of the ophthalmic anterior segment imaging is achieved. The system is adapted to the fundus retinal condition ofmacular degeneration patients, and projects high-resolution images to the area with the lowest retinal photoreceptor cell damage.

According to the invention, a CRISPR gene editing system and an AAV transduction system are utilized to directly knock out an RHO gene from adult macaque retinal photoreceptor cells so as to simulateretinal degeneration degeneration caused by hereditary RHO mutation, and a macaque retinal pigment degeneration (RP) animal model is constructed within 3-6 months. The model can promote research and treatment of human RP diseases.

The invention relates to the technical field of stem cells, and especially relates to a method and kit for identifying retinal progenitor cells capable of treating retinal degenerative change. The method comprises the following steps: culturing retinal progenitor cells to the logarithmic phase, and carrying out flow cytometry identification, wherein the retinal progenitor cells that meet the identification standards are capable of treating retinal degenerative change. The retinal progenitor cells identified by the provided method can maintain a good proliferation performance and stem cell characteristics and have a good curative effect when being applied to the treatment on retinal degenerative change. The experiment results show that after the retinal progenitor cells identified by the provided method are injected into the vitreous body cavities of RCS mice, the retinal outer nuclear layer cells are protected; the multifocal visual electrophysiology examination results show that the change of potential transmitted by retinal photoreceptor cells of the cell injection group is more prominent than the group, which is only injected with a HBSS buffer solution. The water maze experiment results also show that after injection, the visual performance of mice is improved.

The invention discloses a traditional Chinese medicine composition for treating juvenile myopia. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of salvia miltiorrhiza, 6-10 parts of smilax riparia, 6-14 parts of silene conoidea, 11-15 parts of herba pyrolae, 2-4 parts of rhizoma sparganii, 9-13 parts of artemisia anomala, 5-9 parts of astragalus, 3-5 parts of acacia catechu, 6-10 parts of semen cuscutae, 10-20 parts of plantain herb, 2-4 parts of shamrock, 1-3 parts of passion flowers, 4-8 parts of gynostemma pentaphylla and 5-10 parts of paris polyphylla. The traditional Chinese medicine composition disclosed by the invention has the effects of enriching qi and activating blood, tonifying deficiency and tonifying the kidney, nourishing the liver to improve visual acuity and inducing diuresis and reducing edema, so that the liver is full of yin blood, the hepatic and renal functions are normal, the retina photoreceptor cell function is enhanced, the ocular tissues are solid, and neurotrophic factors in the retina and cell layers are increased. Moreover, sufficient nutrition of the eye system is obtained, the ocular material and functional metabolism are normal, the self-healing ability and resistance of the organism are enhanced, the juvenile myopia is fundamentally treated, and the traditional Chinese medicine composition can treat both symptoms and root causes and does not have any toxic and / or side effect.

The invention relates to application of a cannabinoid receptor CB1 in retinal photoreceptor cell degenerative diseases and belongs to the field of gene functions and application. The invention specifies functions of CB1 in retinal photoreceptor cell degenerative diseases such as RP (retinitis pigmentosa) and AMD (age-related macular degeneration), and meanwhile confirms that an inhibitor SR1 of CB1 is capable of effectively alleviating apoptosis of retinal photoreceptors and protecting functions of the cell, so that a CB1 gene can be used as a medicine target for screening medicines for protecting functions of the retinal photoreceptor cell and / or preventing, relieving and treating retinal photoreceptor cell degenerative diseases such as RP and AMD; and the CB1 gene can be used as a targetgene in gene treatment, can be used for designing and preparing medicines and / or biological reagents for protecting functions of the retinal photoreceptor cell and / or preventing, relieving and treating diseases such as RP and AMD, and provides an effective novel way for treatment on retinal photoreceptor cell degenerative diseases.

The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients: 10-30 parts by weight of pilose asiabell root, 3-10 parts by weight of pagodatree pods, 3-15 parts by weight of amur corktree bark, 5-15 parts by weight of flastem milkvetch seeds and 1-3 parts by weight of pearl essence; the Chinese medicine composition preferably further comprises 1-3 parts by weight of amber powder and 6-15 parts by weight of unibract fritillary bulb, wherein pilose asiabell root and flastem milkvetch seeds have the effects of benefiting yang, invigorating spleen and improving eyesight, have the function of increasing retinal photoreceptor cells and are taken as monarch drugs, pagodatree pods and amur corktree bark have the effects of clearing liver, improving eyesight, being bitter and cold and strengthening yin, can clear deficiency-heat of a retinal pigment cell layer and are taken as minister drugs, pearl essence has the effects of calming nerves, consolidating body resistance and reinforcing toughness of a sclera tissue and is taken as an assistant drug, the above drugs form a prescription by taking 'benefiting yang and strengthening yin' as treatment principles, and the traditional Chinese medicine composition has the advantages of simple drug taste, mild drug property, mutual coordination and synergy, and can clear deficiency-heat, solidify eyeball tissues, inhibit sclera deformation and reinforce functions of retinal pigment cells, and further prevent, delay and control the development of myopia.

Methods for ophthalmic lens design incorporating a visual acuity profile are disclosed. The methods include applying rules and functions to visual acuity profile data and an ophthalmic prescription to generate ophthalmic lens parameters for a subject. The visual acuity profile data includes a maximum visual acuity for the subject. The visual acuity profile data may also include a focus tolerance or tolerable blur. Tolerable blur may be measured by an ophthalmic professional or extrapolated. The visual acuity profile data may also include eye physical data such as pupil diameter and eye size, accommodation, retinal photoreceptor cell packing information and neural processing information. The visual acuity profile data may also include personal biographic and / or medical information for the subject.

The invention discloses application of a traditional Chinese medicine composition in relief of asthenopia and prevention, delay and treatment of myopia and complications thereof. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients: 10-30 parts by weight of pilose asiabell root, 3-10 parts by weight of pagodatree pods, 3-15 parts by weight of amur corktree bark, 5-15 parts by weight of flastem milkvetch seeds and 1-3 parts by weight of pearl essence; the traditional Chinese medicine composition preferably further comprises 1-3 parts by weight of amber powder and 6-15 parts by weight of unibract fritillary bulb, wherein pilose asiabell root and flastem milkvetch seeds have the effects of benefiting yang, invigorating spleen and improving eyesight, have the function of increasing retinal photoreceptor cells and are taken as monarch drugs, pagodatree pods and amur corktree bark have the effects of clearing liver, improving eyesight, being bitter and cold and strengthening yin, can clear deficiency-heat of a retinal pigment cell layer and are taken as minister drugs, pearl essence has the effects of calming nerves, consolidating body resistance and reinforcing toughness of a sclera tissue and is taken as an assistant drug, the above drugs form a prescription by taking 'benefiting yang and strengthening yin' as treatment principles, and the traditional Chinese medicine composition has the advantages of simple drug taste, mild drug property, mutual coordination and synergy, and can clear deficiency-heat, solidify eyeball tissues, inhibit sclera deformation and reinforce retinal pigment cells, and further prevent, delay and control the development of myopia.

The invention relates to a co-culture method of photosensory precursor cells and retinal tissue in vitro and aims to build a co-culture system for the photosensory precursor cells and denaturation retinal tissue of retina photoreceptor cells. The method comprises the following steps: a photosensory precursor cell layer of an embryonic eye source is prepared; a nerve cell layer of a denatured retina is prepared; the nerve cell layer of the denatured retina is placed on the photosensory precursor cell layer; an epithelial layer of retinochrome is prepared in the lower chamber of a plug-in type tissue culture dish; the co-culture system of the retinal tissue and cells is built in vitro, and the retinal tissue and cells are cultured in an incubator with 5% CO2 at the temperature of 37 DEG C. By adopting the method provided by the invention, the biological characteristics and cellular structure of host cells and transplanted cells, the synaptic contact of the transplanted cells and the host cells, and the chromatin conformation reconstruction of the transplanted cells and the host cells can be observed and detected directly in vitro, and the traces of survival, proliferation, differentiation and functional reconstruction of photosensory precursor cells of a transplanted embryonic eye source can be tracked.

The invention relates to the field of molecular biology and biomedicine, in particular to a method for preparing a CRX mutation related retinopathy non-human mammal model. The method comprises the step of expressing CRX[S204fs] protein in retina photoreceptor cells of an animal by adopting a transgenic method. The CRX[S204fs] protein has a competitive antagonism effect (type-III mutation) on wildtype protein, so that retinopathy symptoms can be shown as long as the CRX[S204fs] protein is expressed in the animal body, a wild type CRX gene does not need to be knocked out, and construction of the animal model is simpler, quicker and more economical.

The invention discloses a traditional Chinese medicine composition for treating juvenile myopia. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of salvia miltiorrhiza, 6-10 parts of smilax riparia, 6-14 parts of silene conoidea, 11-15 parts of herba pyrolae, 2-4 parts of rhizoma sparganii, 9-13 parts of artemisia anomala, 5-9 parts of astragalus, 3-5 parts of acacia catechu, 6-10 parts of semen cuscutae, 10-20 parts of plantain herb, 2-4 parts of shamrock, 1-3 parts of passion flowers, 4-8 parts of gynostemma pentaphylla and 5-10 parts of paris polyphylla. The traditional Chinese medicine composition disclosed by the invention has the effects of enriching qi and activating blood, tonifying deficiency and tonifying the kidney, nourishing the liver to improve visual acuity and inducing diuresis and reducing edema, so that the liver is full of yin blood, the hepatic and renal functions are normal, the retina photoreceptor cell function is enhanced, the ocular tissues are solid, and neurotrophic factors in the retina and cell layers are increased. Moreover, sufficient nutrition of the eye system is obtained, the ocular material and functional metabolism are normal, the self-healing ability and resistance of the organism are enhanced, the juvenile myopia is fundamentally treated, and the traditional Chinese medicine composition can treat both symptoms and root causes and does not have any toxic and / or side effect.

The invention relates to a method for inducing the differentiation of human amniotic epithelial cells into retinal photoreceptor cells and its application in treating retinal degenerative diseases. The invention provides a method for inducing the differentiation of human amniotic epithelial cells into retinal photoreceptor cells, culturing human amniotic epithelial cells under suitable conditions, adding an inducing composition to induce the differentiation of human amniotic epithelial cells into retinal photoreceptor cells, and inducing the cells produced High expression of typical genes of retinal photoreceptor cells such as Chx10, Rx, Crx, NRL. After the induced differentiation cells were collected and injected into the subretinal space, the electrophysiological signals of the eye were significantly enhanced, the fundus structure was significantly improved, and the retinal thickness was significantly increased through ERG and OCT detection, which showed that it could treat and / or improve the progress of retinal degenerative diseases. The clinical application of ophthalmic diseases will have broad prospects.

The invention discloses an application of a traditional Chinese medicine composition in alleviating visual fatigue and preventing, delaying and treating myopia and its complications. Part Huaijiao, 3-15 parts by weight Phellodendron Phellodendri, 5-15 parts by weight Shayuanzi and 1-3 parts by weight pearl powder, preferably also include 1-3 parts by weight amber powder and 6-15 parts by weight Chuan Fritillaria. Among them, Dangshen and Shayuanzi benefit yang, invigorate the spleen and improve eyesight, and increase the function of retinal photoreceptor cells are the monarch drugs; Huaijiao and Cortex Phellodendri can clear the liver and improve eyesight, bitter cold and harden yin, and clear the deficiency heat of the retinal pigment cell layer are the ministerial drugs; pearl powder calms the nerves and strengthens the body , to strengthen the tenacity of scleral tissue as an adjuvant drug, the above-mentioned medicinal materials are formulated with "Yin Yang Jian Yin" as the treatment principle, the taste of the medicine is simple, the property of the medicine is mild, and they cooperate with each other and act synergistically. Inhibit the deformation of sclera, strengthen the function of retinal pigment cells, so as to prevent, delay and control the development of myopia.

The invention relates to a method constructed for verifying retina photoreceptor cell specific surface protein. By utilizing the method provided by the invention, purified precursor cells of the photoreceptor cells are analyzed and screened to obtain the specific surface protein of the photoreceptor cells; the specific surface protein is specifically expressed on membrane surfaces of retina photoreceptor cells from human embryonic stem cells and human pluripotent stem cells, so that the induced human embryonic stem cells or the photoreceptor cells from the human pluripotent stem cells are purified by utilizing the specific surface protein. The purified photoreceptor cells are obtained through screening the surface protein and potential hazards caused by the fact that transgenosis is carried out or various small molecule compounds are used as an induction agent can be avoided. The key scientific problem is solved and a process of converting stem cells to clinical application is accelerated; requirements of medical researches are met and a foundation is laid for cell replacement therapy of human retina related diseases (such as glaucoma and macular eye diseases).

The invention relates to the construction and application of an animal model of chronic drug toxicity retinal photoreceptor cell damage, and aims to solve the technical problem that there is no relevant animal model in the prior art. The present invention mainly constructs an animal model of chronic drug toxicity retinal photoreceptor cell damage by injecting methyl methanesulfonate into the tail vein of mice at a dosage of 40-60 / (kg·body weight). The invention establishes an animal model of chronic drug retinal photoreceptor cell injury for the first time, and can provide a reliable and stable animal model for studying the molecular regulation effect of epigenetic modification on the transdifferentiation and regeneration of endogenous stem cells in the process of retinal injury, pathogenesis and intervention therapy It also lays a material and technical foundation for people to more effectively understand the mechanism and development of retinal drug toxicity diseases and to study intervention and treatment measures.

Methods for ophthalmic lens design incorporating a visual acuity profile are disclosed. The methods include applying rules and functions to visual acuity profile data and an ophthalmic prescription to generate ophthalmic lens parameters for a subject. The visual acuity profile data includes a maximum visual acuity for the subject. The visual acuity profile data may also include a focus tolerance or tolerable blur. Tolerable blur may be measured by an ophthalmic professional or extrapolated. The visual acuity profile data may also include eye physical data such as pupil diameter and eye size, accommodation, retinal photoreceptor cell packing information and neural processing information. The visual acuity profile data may also include personal biographic and / or medical information for the subject.

The invention relates to the technical field of stem cells, and especially relates to a method and kit for identifying retinal progenitor cells capable of treating retinal degenerative change. The method comprises the following steps: culturing retinal progenitor cells to the logarithmic phase, and carrying out flow cytometry identification, wherein the retinal progenitor cells that meet the identification standards are capable of treating retinal degenerative change. The retinal progenitor cells identified by the provided method can maintain a good proliferation performance and stem cell characteristics and have a good curative effect when being applied to the treatment on retinal degenerative change. The experiment results show that after the retinal progenitor cells identified by the provided method are injected into the vitreous body cavities of RCS mice, the retinal outer nuclear layer cells are protected; the multifocal visual electrophysiology examination results show that the change of potential transmitted by retinal photoreceptor cells of the cell injection group is more prominent than the group, which is only injected with a HBSS buffer solution. The water maze experiment results also show that after injection, the visual performance of mice is improved.